Amgen Statistics
Total Valuation
Amgen has a market cap or net worth of $175.08 billion. The enterprise value is $220.36 billion.
| Market Cap | 175.08B |
| Enterprise Value | 220.36B |
Important Dates
The last earnings date was Thursday, April 30, 2026, after market close.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | May 15, 2026 |
Share Statistics
Amgen has 539.71 million shares outstanding. The number of shares has increased by 0.09% in one year.
| Current Share Class | 539.71M |
| Shares Outstanding | 539.71M |
| Shares Change (YoY) | +0.09% |
| Shares Change (QoQ) | +0.18% |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 81.74% |
| Float | 538.23M |
Valuation Ratios
The trailing PE ratio is 22.58 and the forward PE ratio is 14.31. Amgen's PEG ratio is 3.09.
| PE Ratio | 22.58 |
| Forward PE | 14.31 |
| PS Ratio | 4.70 |
| Forward PS | 4.50 |
| PB Ratio | 19.05 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 20.36 |
| P/OCF Ratio | 16.28 |
| PEG Ratio | 3.09 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.03, with an EV/FCF ratio of 25.63.
| EV / Earnings | 28.25 |
| EV / Sales | 5.92 |
| EV / EBITDA | 13.03 |
| EV / EBIT | 18.14 |
| EV / FCF | 25.63 |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 6.24.
| Current Ratio | 1.26 |
| Quick Ratio | 0.85 |
| Debt / Equity | 6.24 |
| Debt / EBITDA | 3.34 |
| Debt / FCF | 6.67 |
| Interest Coverage | 3.92 |
Financial Efficiency
Return on equity (ROE) is 101.32% and return on invested capital (ROIC) is 19.05%.
| Return on Equity (ROE) | 101.32% |
| Return on Assets (ROA) | 8.35% |
| Return on Invested Capital (ROIC) | 19.05% |
| Return on Capital Employed (ROCE) | 17.98% |
| Weighted Average Cost of Capital (WACC) | 6.15% |
| Revenue Per Employee | $1.18M |
| Profits Per Employee | $247,619 |
| Employee Count | 31,500 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 1.65 |
Taxes
In the past 12 months, Amgen has paid $1.29 billion in taxes.
| Income Tax | 1.29B |
| Effective Tax Rate | 14.16% |
Stock Price Statistics
The stock price has increased by +19.08% in the last 52 weeks. The beta is 0.44, so Amgen's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | +19.08% |
| 50-Day Moving Average | 347.04 |
| 200-Day Moving Average | 326.44 |
| Relative Strength Index (RSI) | 36.90 |
| Average Volume (20 Days) | 2,677,791 |
Short Selling Information
The latest short interest is 12.97 million, so 2.40% of the outstanding shares have been sold short.
| Short Interest | 12.97M |
| Short Previous Month | 12.74M |
| Short % of Shares Out | 2.40% |
| Short % of Float | 2.41% |
| Short Ratio (days to cover) | 5.14 |
Income Statement
In the last 12 months, Amgen had revenue of $37.22 billion and earned $7.80 billion in profits. Earnings per share was $14.37.
| Revenue | 37.22B |
| Gross Profit | 26.59B |
| Operating Income | 12.15B |
| Pretax Income | 9.09B |
| Net Income | 7.80B |
| EBITDA | 16.92B |
| EBIT | 12.15B |
| Earnings Per Share (EPS) | $14.37 |
Balance Sheet
The company has $12.04 billion in cash and $57.32 billion in debt, with a net cash position of -$45.29 billion or -$83.91 per share.
| Cash & Cash Equivalents | 12.04B |
| Total Debt | 57.32B |
| Net Cash | -45.29B |
| Net Cash Per Share | -$83.91 |
| Equity (Book Value) | 9.19B |
| Book Value Per Share | 17.03 |
| Working Capital | 6.52B |
Cash Flow
In the last 12 months, operating cash flow was $10.76 billion and capital expenditures -$2.16 billion, giving a free cash flow of $8.60 billion.
| Operating Cash Flow | 10.76B |
| Capital Expenditures | -2.16B |
| Depreciation & Amortization | 4.77B |
| Net Borrowing | 16.00M |
| Free Cash Flow | 8.60B |
| FCF Per Share | $15.93 |
Margins
Gross margin is 71.44%, with operating and profit margins of 32.63% and 20.96%.
| Gross Margin | 71.44% |
| Operating Margin | 32.63% |
| Pretax Margin | 24.41% |
| Profit Margin | 20.96% |
| EBITDA Margin | 45.45% |
| EBIT Margin | 32.63% |
| FCF Margin | 23.10% |
Dividends & Yields
This stock pays an annual dividend of $10.08, which amounts to a dividend yield of 3.11%.
| Dividend Per Share | $10.08 |
| Dividend Yield | 3.11% |
| Dividend Growth (YoY) | 5.83% |
| Years of Dividend Growth | 16 |
| Payout Ratio | 68.21% |
| Buyback Yield | -0.09% |
| Shareholder Yield | 3.02% |
| Earnings Yield | 4.46% |
| FCF Yield | 4.91% |
Analyst Forecast
The average price target for Amgen is $352.23, which is 8.58% higher than the current price. The consensus rating is "Buy".
| Price Target | $352.23 |
| Price Target Difference | 8.58% |
| Analyst Consensus | Buy |
| Analyst Count | 35 |
| Revenue Growth Forecast (5Y) | 2.69% |
| EPS Growth Forecast (5Y) | 10.79% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 22, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Nov 22, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Amgen has an Altman Z-Score of 1.75 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.75 |
| Piotroski F-Score | 8 |